Calendar

««Jan 2009»»
SMTWTFS
     12
3
45678910
11121314151617
18192021222324
25262728293031
  More

Search Box

 

cbt and mindfulness

Mailing List

RSS Feeds








Add to Jamespot
Widgetize!

Translate



Link to Ai profile Link to Anxiety Community Link to Wellsphere

Health Wisdom

HealthCentral Top Site Award

IBS Tales Hope Award

Disclaimer

All content within Anxiety Insights is provided for general information only, and should not be treated as a substitute for the medical advice of your doctor or other health care professional.

Anxiety Insights is not responsible or liable for any diagnosis made by a reader based on the content of this website.

Anxiety Insights is not liable for the contents of any external internet sites listed, nor does it endorse any commercial product or service mentioned or advised on any of the sites.

Always consult your doctor if you are in any way concerned about your health.

recommended links

Depression is Real's Down & Up Show
      Weekly audio-casts from the
      Depression Is Real Coalition

we support

Kiva.org - micro loans that change lives

Moving a Nation to Care : Post Traumatic Stress Disorder and America's Returning Troops, by Ilona Meagher

No Longer Lonely.com

"just don't smoke"


"Don't smoke, whatever you do, just don't smoke."
                        Yul Brynner

Hit Counter

Total: 2,013,455
since: 14 May 2006

Serotonin: The 'chemical imbalance' myth


The chemical hypothesis of anxiety and depression proposes that these disorders are caused by too little of a neurotransmitter, usually serotonin, in the brain, which is corrected by antidepressant drugs.

Its been known for more than a decade that the 'chemical imbalance/low serotonin' theory was deeply flawed, yet in continues to be promoted in the media and even medical journals.

Serotonergic antidepressants do increase serotonin levels both in synapses and the brain overall within about 30 minutes of the first dose, and levels may remain higher for some weeks. But they drop back to baseline or below at about the time patients begin to feel an improvement in anxiety or depression, usually some 4 to 12 weeks after beginning treatment.1

The fact that the boost in serotonin doesn't immediately alleviate anxiety and depression is the first clue that there is more to these disorders than just a lack of serotonin.

Perhaps, the best indicator that increasing serotonin levels isn't the factor responsible for the therapeutic effect of antidepressants is the French drug tianeptine (Stablon®), a Selective Serotonin Re-Uptake Enhancer/Accelerator. That is, it speeds up the removal of serotonin from the synapses. Yet, it is as effective as Selective Serotonin Re-uptake Inhibitors such as Prozac®, which delay removal of the neurotransmitter.

Further evidence against the hypothesis comes from rat models of depression. Rats bred to have a high genetic predisposition for depression have up to 8 times more serotonin in brain regions associated with anxiety disorders and clinical depression - the nucleus accumbens, prefrontal cortex, hippocampus, and hypothalamus - than controls.2 Chronic antidepressant treatment reduces serotonin to levels found in normal rats.

How antidepressants work is still a matter of debate. The most likely current theory is that they do so by stimulating neurogenesis - the formation of new neurons, especially in the hippocampus, and encouraging increased nerve-fiber innervation between limbic structures and the forebrain.

It wouldn't matter how antidepressants work, just as long as they do, except that the 'chemical imbalance' theory is used to promote sales of the serotonin precursors L-Tryptophan and 5-HTP which not only can't work as advertised, but which, at least in the case of L-Tryptophan, may cause harm through the contaminate, Peak-X. Peak-X is though to trigger the immune system disorder Eosinophilia-myalgia syndrome (EMS). L-Tryptophan linked EMS caused the deaths of 37 people in the late 1980s and permanently damaged the health of another 1,500+.

Despite claims that Peak-X contamination was confined to a few batched produced by one manufacturer, Simat et al found markers for Peak-X in pharmaceutical grade L-Tryptophan on sale in Germany in 1998. A 2001 U.S. Food and Drug Administration (FDA) Information Paper on L-tryptophan and 5-hydroxy-L-tryptophan (5-HTP) contains more information on the current thinking about these supplements.


See also:


Abstract+: The media and the chemical imbalance theory


The "Chemical Imbalance" Explanation for Depression: Origins, Lay Endorsement, and Clinical Implications (PDF format)



References:  
(Note 5-HT = serotonin)
  1. Bianchi M, Moser C, Lazzarini C, Vecchiato E, Crespi F. (2002)
    Forced swimming test and fluoxetine treatment: in vivo evidence that peripheral 5-HT in rat platelet-rich plasma mirrors cerebral extracellular 5-HT levels, whilst 5-HT in isolated platelets mirrors neuronal 5-HT changes.
    Exp Brain Res. 2002 Mar;143(2):191-7. [Abstract]

    Stenfors C, Yu H, Ross SB. (2001)
    Pharmacological characterisation of the decrease in 5-HT synthesis in the mouse brain evoked by the selective serotonin re-uptake inhibitor citalopram.
    Naunyn Schmiedebergs Arch Pharmacol, vol 363(2):p 222-32 [Abstract]

    Alvarez JC, Sanceaume M, Advenier C, et al. (1999)
    Differential changes in brain and platelet 5-HT concentrations after steady-state achievement and repeated administration of antidepressant drugs in mice.
    Eur Neuropsychopharmacol, vol 10(1):p 31-6 [Abstract]

    Moret C, Briley M.
    Ex vivo inhibitory effect of the 5-HT uptake blocker citalopram on 5-HT synthesis.
    J Neural Transm. 1997;104(2-3):147-60. [Abstract]

    Trouvin JH, Gardier AM, Chanut E, et al. (1993)
    Time course of brain serotonin metabolism after cessation of long-term fluoxetine treatment in the rat.
    Life Sci, vol 52(18):p PL187-92 [Abstract]

    Caccia S, Anelli M, Codegoni AM, Fracasso C, Garattini S. (1993)
    The effects of single and repeated anorectic doses of 5-hydroxytryptamine uptake inhibitors on indole levels in rat brain.
    Br J Pharmacol. 1993 Sep;110(1):355-9. [Abstract]

    Caccia S, Fracasso C, Garattini S, Guiso G, Sarati S. (1992)
    Effects of short- and long-term administration of fluoxetine on the monoamine content of rat brain.
    Neuropharmacology. 1992 Apr;31(4):343-7. [Abstract]

    Leonard BE. (1988)
    Pharmacological effects of serotonin reuptake inhibitors.
    J Clin Psychiatry. 1988 Aug;49 Suppl:12-7. [Abstract]

  2. Zangen A, Overstreet DH, Yadid G. (1997)
    High serotonin and 5-hydroxyindoleacetic acid levels in limbic brain regions in a rat model of depression: normalization by chronic antidepressant treatment.
    J Neurochem, vol 69(6):p 2477-83 [Abstract]